On-Demand CME Videos
Moderate-to-Severe Atopic Dermatitis in Children and Adolescents: Stop the Itch that Rashes: Online CME Activity
About
This activity was recorded at the 2022 Fall Clinical Dermatology Conference on October 22, 2022.
CME Satellite Symposium: Moderate-to-Severe Atopic Dermatitis in Children and Adolescents: Stop the Itch that Rashes
This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.
Availability
In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:
November 15, 2022
November 15, 2024
Learning Objectives
At the completion of this activity, participants should be better able to:
Overview the key data on systemic biologics for the management of moderate-to-severe atopic dermatitis in children and adolescents
Identify children and adolescents who would benefit from biologics for the management of moderate-to-severe atopic dermatitis
Describe strategies to integrate biologics into daily clinical practice to effectively manage moderate-to-severe AD
Intended Audience
Faculty
Benjamin Lockshin, MD
EVP of Strategic Initiatives
Director of the Clinical Trials Center
Assistant Professor
US Dermatology Partners
Georgetown University
Rockville, MD
Mona Shahriari, MD
Dermatologist
Central CT Dermatology
Cromwell, CT
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada and CMEsquared. The University of Nevada is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Nevada designates this enduring activity for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
CONFLICTS OF INTEREST/DISCLOSURES
In accordance with the ACCME Standards for Commercial Support, balance, independence, objectivity, and scientific rigor are ensured in all CME activities. This requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with any ineligible companies. In addition, the content of this material has been approved by an independent peer reviewer.
Disclosures are as follows:
Grant/Research Support: Abbvie, Eli Lilly, Celgene, Regeneron, Sanofi Genzyme, DermTech, Exact Sciences, Pfizer, Leo, Arcutis, Dermavant
Consultant: AbbVie, Eli Lilly, Regeneron, Sanofi Genzyme, DermTech, Exact Sciences, Dermavant, Arcutis, Leo
Speakers’ Bureau or Honoraria: Abbvie, Eli Lilly, Regeneron, Sanofi Genzyme, Dermavant, Arcutis, Leo
Grant/Research Support: AbbVie, Dermira, Cara, Dermavant, Novartis, Union
Consultant: Abbvie, BMS, Dermavant, Leo, Lilly, Sanofi, Regeneron, UCB
Speakers’ Bureau or Honoraria: Abbvie, BMS, Lilly, Leo, Janssen, Dermavant
The planners have disclosed that they have no relevant financial relationships with any Ineligible Company in the past 24 months.
The University of Nevada discloses that all relevant conflicts have been satisfactorily mitigated.